7.38 USD
+0.48 (+6.96%)
7.2003 USD
-0.18 (-2.43%)
Taking everything into account, MYGN scores 3 out of 10 in our fundamental rating. MYGN was compared to 535 industry peers in the Biotechnology industry. Both the profitability and financial health of MYGN have multiple concerns. MYGN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MYGN had positive earnings in the past year.
MYGN had a negative operating cash flow in the past year.
MYGN had negative earnings in each of the past 5 years.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of MYGN (-55.01%) is comparable to the rest of the industry.
The Return On Equity of MYGN (-107.43%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROIC | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN has a better Gross Margin (70.36%) than 81.43% of its industry peers.
In the last couple of years the Gross Margin of MYGN has declined.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYGN has more shares outstanding than it did 1 year ago.
MYGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MYGN is higher compared to a year ago.
2.2 Solvency
MYGN has an Altman-Z score of 0.03. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
MYGN has a Altman-Z score of 0.03. This is in the better half of the industry: MYGN outperforms 62.66% of its industry peers.
MYGN has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
MYGN has a Debt to Equity ratio of 0.32. This is in the lower half of the industry: MYGN underperforms 69.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.03 |
ROIC/WACCN/A
WACC8.48%
2.3 Liquidity
A Current Ratio of 2.33 indicates that MYGN has no problem at all paying its short term obligations.
MYGN has a worse Current ratio (2.33) than 70.73% of its industry peers.
MYGN has a Quick Ratio of 2.12. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.12, MYGN is not doing good in the industry: 71.86% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
The earnings per share for MYGN have decreased strongly by -64.29% in the last year.
MYGN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 86.63% yearly.
MYGN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.21%.
MYGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.32% yearly.
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
3.2 Future
Based on estimates for the next years, MYGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.77% on average per year.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 3.25% on average per year.
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y15.77%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.25%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MYGN is valuated quite expensively with a Price/Earnings ratio of 147.60.
MYGN's Price/Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 89.12% of the companies in the same industry.
MYGN is valuated expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 70.30, the valuation of MYGN can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MYGN indicates a rather cheap valuation: MYGN is cheaper than 88.18% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of MYGN to the average of the S&P500 Index (34.46), we can say MYGN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.6 | ||
| Fwd PE | 70.3 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MYGN's earnings are expected to grow with 18.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.38
+0.48 (+6.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.36%
Inst Owner Change-0.3%
Ins Owners2.62%
Ins Owner Change7.93%
Market Cap686.64M
Revenue(TTM)825.30M
Net Income(TTM)-400.50M
Analysts53.68
Price Target7.48 (1.36%)
Short Float %7.96%
Short Ratio5.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)363.83%
Min EPS beat(2)100%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)193.66%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)222.43%
EPS beat(12)10
Avg EPS beat(12)156.03%
EPS beat(16)13
Avg EPS beat(16)126.64%
Revenue beat(2)1
Avg Revenue beat(2)0.96%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-1.19%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.37%
Revenue beat(12)6
Avg Revenue beat(12)0.38%
Revenue beat(16)8
Avg Revenue beat(16)-0.17%
PT rev (1m)2.32%
PT rev (3m)1.96%
EPS NQ rev (1m)-197.6%
EPS NQ rev (3m)-109.73%
EPS NY rev (1m)-24.88%
EPS NY rev (3m)146.2%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 147.6 | ||
| Fwd PE | 70.3 | ||
| P/S | 0.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | 4.34 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.05
EY0.68%
EPS(NY)0.1
Fwd EY1.42%
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS8.87
BVpS4.01
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.36% | ||
| FCFM | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.14% | ||
| Cap/Sales | 3.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.33 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 0.03 |
F-Score5
WACC8.48%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-64.29%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y15.77%
Revenue 1Y (TTM)0.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%-3.56%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.25%
EBIT growth 1Y13.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.33%
EBIT Next 3Y42.66%
EBIT Next 5Y15.6%
FCF growth 1Y78.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y96.09%
OCF growth 3YN/A
OCF growth 5YN/A
MYRIAD GENETICS INC / MYGN FAQ
What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MYGN.
Can you provide the valuation status for MYRIAD GENETICS INC?
ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.
Can you provide the profitability details for MYRIAD GENETICS INC?
MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.
How financially healthy is MYRIAD GENETICS INC?
The financial health rating of MYRIAD GENETICS INC (MYGN) is 3 / 10.